SRK-015 (Scholar Rock) Updates

SRK-015 is a muscle-directed therapy that aims to reverse or restrict the muscle atrophy and weakness experienced by SMA patients. The drug is an antibody that very specifically targets an important protein called myostatin.

 

2020

13th May:
Scholar Rock Reports Delays in Interim Trial Results Due to COVID-19

14th January:
Scholar Rock Summarises Progress To Date With SRK-015

 

2019

25th November:
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of SMA

18th March:
Positive Interim Results from Phase I Trial Announced by Scholar Rock
 

2018

4th Dec: SCHOLAR ROCK ANNOUNCE SRK-015 ORPHAN DRUG DESIGNATION NEWS AND PUBLISH PRE-CLINICAL DATA

8th June: First Cohort Dosing Completed in SRK-015 Phase 1 Clinical Trial

3rd May: SCHOLAR ROCK EXPERIMENTAL DRUG FOR SMA GRANTED ORPHAN DRUG STATUS